Bavarian Nordic Receives NIH Grant to Investigate the Potential of an MVA-BN based Vaccine against Ebola and Marburg Viruses

18-Oct-2010 - Denmark

Bavarian Nordic A/S announced that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus).

As previously announced, the company is investigating the potential use of its core vaccine technology, MVA-BN® as a combined vaccine encoding genes for both the Ebola and Marburg strains. The funding from NIH will support an animal efficacy study performed in non-human primates.

Upon evaluation of the initial data from this study, which are expected next year, Bavarian Nordic will determine the future of this project in the company's pipeline.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Last viewed contents